|
Dec 15
|
Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock?
|
|
Dec 11
|
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
|
|
Dec 10
|
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
|
|
Dec 9
|
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
|
|
Dec 1
|
bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How
|
|
Nov 29
|
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
|
|
Nov 26
|
2 Biotech Stocks That Could Soar in December
|
|
Jul 20
|
4 big analyst picks: AMD called a 'Top Pick' at Wolfe; Cisco upped at JPMorgan
|
|
Jul 19
|
Why Bluebird Bio Stock Is Taking Flight Today
|
|
Apr 27
|
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
|
|
Apr 24
|
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
|